Overview

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Status:
Completed

Trial end date:
2016-02-28

Target enrollment:

Participant gender:

Summary

This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Treatments:

Hormones
Radium Ra 223 dichloride
Succinylcholine